Login
Registrati
Reimposta password
Pubblica & Distribuisci
Soluzioni Editoriali
Soluzioni di Distribuzione
Temi
Architettura e design
Arti
Business e Economia
Chimica
Chimica industriale
Farmacia
Filosofia
Fisica
Geoscienze
Ingegneria
Interesse generale
Legge
Letteratura
Linguistica e semiotica
Matematica
Medicina
Musica
Scienze bibliotecarie e dell'informazione, studi library
Scienze dei materiali
Scienze della vita
Scienze informatiche
Scienze sociali
Sport e tempo libero
Storia
Studi classici e del Vicino Oriente antico
Studi culturali
Studi ebraici
Teologia e religione
Pubblicazioni
Riviste
Libri
Atti
Editori
Blog
Contatti
Cerca
EUR
USD
GBP
Italiano
English
Deutsch
Polski
Español
Français
Italiano
Carrello
Home
Riviste
Asian Biomedicine
Volume 18 (2024): Numero 2 (April 2024)
Accesso libero
Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo
Shenglin Lu
Shenglin Lu
e
Jun Li
Jun Li
| 30 apr 2024
Asian Biomedicine
Volume 18 (2024): Numero 2 (April 2024)
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Sommario
Articolo
Immagini e tabelle
Bibliografia
Autori
Articoli in questo Numero
Anteprima
PDF
Cita
CONDIVIDI
Article Category:
Original article
Pubblicato online:
30 apr 2024
Pagine:
61 - 68
DOI:
https://doi.org/10.2478/abm-2024-0009
Parole chiave
cholangiocarcinoma
,
matrix metalloproteinase
,
mouse
,
treatment
,
vascular endothelial growth factor
© 2024 Shenglin Lu et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1.
Sequencing results of pGCsiRNA-VEGF containing U6 promoter. The results showed that 6.3 kb linearized vectors and 63 bp oligonucleotide fragments were obtained. pGCsiRNA, VEGF, vascular endothelial growth factor.
Figure 2.
Tumor growth curves. The tumor volume was smaller in the pGCsiRNA-VEGF group than that in the mock group and the si-scramble group on Day 27 of treatment. VEGF, vascular endothelial growth factor.
Figure 3.
Tumor weights. On Day 28 of treatment, the tumor weight was smaller in the pGCsiRNA-VEGF group than that in the mock group and the si-scramble group. VEGF, vascular endothelial growth factor.
Figure 4.
Tumor volumes. Tumor growth was inhibited in nude mice. VEGF, vascular endothelial growth factor.
Figure 5.
Protein expressions of VEGF, MMP2 and MMP9. The protein expressions of VEGF, MMP2, and MMP9 declined in pGCsiRNA-VEGF group compared with those in the mock and si-scramble groups. MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor.
Figure 6.
Changes in mRNA expressions of VEGF, MMP2, and MMP9 in tumor tissues. The mRNA expressions of VEGF, MMP2, and MMP9 were significantly lower in the pGCsiRNA-VEGF group than those in the mock group and the si-scramble group. MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor.
Figure 7.
Morphological changes of tumor tissues. There was obvious apoptosis of tumor tissues, a large number of cells died, the tissue structures mostly disappeared, karyopyknosis was found, a large number of apoptotic cells were dispersed around the tissues, and the cells lost their normal morphology in pGCsiRNA-VEGF group compared to those in the mock and si-scramble groups. VEGF, vascular endothelial growth factor.
Figure 8.
VEGF expressions of the different groups. The protein expression of VEGF was significantly suppressed in the pGCsiRNA-VEGF group compared with that in the mock group and the si-scramble group. VEGF, vascular endothelial growth factor.